Stockscreener 앱 받기
1.56%
전일 마감가:
$25.07
열려 있는:
$25.07
하루 거래량:
13.19M
Relative Volume:
0.34
시가총액:
$140.38B
수익:
$63.83B
순이익/손실:
$10.77B
주가수익비율:
13.14
EPS:
1.88
순현금흐름:
$12.44B
1주 성능:
-4.12%
1개월 성능:
+1.52%
6개월 성능:
-6.62%
1년 성능:
-14.16%
1일 변동 폭
$24.65
$25.07
1주일 범위
$24.65
$26.11
52주 변동 폭
$20.91
$30.43
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.69 | 141.68B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
733.06 | 659.82B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
175.18 | 425.05B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
206.83 | 368.08B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.59 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
83.04 | 212.29B | 63.43B | 16.42B | 14.72B | 6.49 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Pfizer: A 6% Dividend Yield That Pays You To Stay Defensive (NYSE:PFE) - Seeking Alpha
Prasad explains why FDA revoked Pfizer’s Covid vaccine EUA for children - Endpoints News
Developing predictive dashboards with Pfizer Inc. dataPortfolio Update Summary & Weekly High Return Stock Opportunities - Newser
Relative strength of Pfizer Inc. in sector analysis2025 Dividend Review & Community Shared Stock Ideas - Newser
Advanced analytics toolkit walkthrough for Pfizer Inc.July 2025 Retail & Capital Efficiency Focused Ideas - Newser
Pfizer Faces Patent Infringement Lawsuit Over COVID-19 Antiviral Paxlovid - AInvest
Stock Analysis | Pfizer OutlookMixed Signals as Technicals Worsen Despite Strong Fundamentals - AInvest
Price momentum metrics for Pfizer Inc. explainedWeekly Gains Summary & Weekly Watchlist for Consistent Profits - Newser
Is Pfizer Inc. trending in predictive chart modelsWeekly Stock Recap & Target Return Focused Picks - Newser
Advanced analytics toolkit walkthrough for Pfizer IncEarnings Overview Summary & Daily Profit Maximizing Tips - Newser
Morgan Stanley Lifts Pfizer (PFE) Price Target, Keeps Equalweight Rating - Yahoo Finance
Houston woman sues Pfizer, claims birth control shot caused brain tumor - FOX 26 Houston
Measuring Pfizer Inc.’s beta against major indices2025 Price Momentum & Daily Market Momentum Tracking - Newser
Pfizer: Is Its 6.8% Dividend a Value Trap or a Golden Opportunity? - AInvest
Pfizer's Put Puzzler: Bearish Bets or Contrarian Gold? - AInvest
Pfizer: Finally Some Fortune, Plus Twenty High-Quality Dividend Growth Valuations (PFE) - Seeking Alpha
FDA approves updated COVID-19 shots with limits for some kids and adults - Greenwich Time
Pfizer lays off 100 employees in Bothell, cites growth in automation, efficiency - Yahoo Finance
FDA Approves BioNTech and Pfizer’s New COVID-19 Vaccine for High-Risk Groups - TipRanks
What institutional flow reveals about Pfizer Inc.IPO Watch & Free Technical Pattern Based Buy Signals - Newser
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines - Benzinga
Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population - Stocktwits
US Approves Latest Covid Shots With Limits on Who Gets Them - MSN
Unusual Put Option Activity in Pfizer StockHave Investors Turned Bearish? - MSN
FDA Approves Pfizer & BioNTech’s Updated COVID-19 Vaccine for High-Risk Groups - Contract Pharma
FDA Approves Pfizer Covid Vaccine but Adds Restrictions on Its Use - Barron's
FDA approves updated COVID-19 shots but limits access for some kids and adults - WKBN.com
Unusual Put Option Activity In Pfizer StockHave Investors Turned Bearish? - Barchart.com
Pfizer's mRNA Revolution: A Catalyst for Biopharma's Next Era - AInvest
FDA approves updated Pfizer COVID shots but limits access for some kids and adults - KOAT
Global Pharmaceuticals Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight - GlobeNewswire Inc.
Pfizer, BioNTech Get FDA Approval for Covid Vaccine - MarketScreener
US health officials approve Pfizer's updated COVID-19 shot, but with limits for many adults and children - Daily Jefferson County Union
FDA Approves Next-Gen COVID Vaccine: Pfizer-BioNTech's COMIRNATY Targets New LP.8.1 Variant for 2025 - Stock Titan
Robert Kennedy Jr. Announces End Of FDA Covid Mandates – Clears Moderna, Pfizer, Novavax For High-Risk Groups - Stocktwits
US FDA says Pfizer discontinues manufacturing of Dobutamine Hydrochloride Injection - MarketScreener
Applying Wyckoff theory to Pfizer Inc. stockJuly 2025 Movers & Real-Time Volume Analysis Alerts - Newser
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months' - Yahoo Finance
UPC covid caseload grows as Pfizer faces fresh action by Enanta - IAM Media
Real time pattern detection on Pfizer Inc. stock2025 Year in Review & Risk Controlled Swing Trade Alerts - Newser
Enanta's 15-minute chart triggers KDJ Golden Cross, bullish Marubozu signal. - AInvest
Nerve Growth Factor Market: Epidemiology, Therapies, Companies, DelveInsight | Dompé farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega - Barchart.com
Using economic indicators to assess Pfizer Inc. potentialExit Point & Consistent Return Investment Signals - Newser
Why Pfizer Inc. is moving todayPortfolio Performance Report & Accurate Technical Buy Alerts - Newser
Pfizer patents new GIPR antagonists - BioWorld MedTech
Pfizer to Cut Another 100 Seattle-Area Workers in August - NEWStalk 870
Is There Now an Opportunity in Pfizer After FDA Covid Vaccine Review for Children? - Yahoo Finance
Moderna stock falls, Pfizer dips on COVID vaccine ban speculation - Investing.com
Using flow based indicators on Pfizer Inc.July 2025 Institutional & Fast Entry and Exit Trade Plans - Newser
Pfizer's Credibility Discount: A Clear Buying Opportunity (NYSE:PFE) - Seeking Alpha
Pfizer Says FDA Blocked Tumor Warnings For Depo-Provera - Law360
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
자본화:
|
볼륨(24시간):